Conference call and webcast: today, May 23, 2024, 9:00 am
ET
Financial and Business Highlights:
- Q1 2024 revenue: $4.2M vs.
$0.6M in Q1 2023; anticipating
continued growth in 2024.
- Q1 2024 net loss: $3.8M vs.
$7.0M in Q1 2023.
- Projected 2024 cash usage, excluding Lavie Bio and
Biomica: $8.0M, down 36% from
$12.5M in 2023.
- Ceasing Canonic's operations results in annualized
savings of approximately $1.5
million.
- Casterra's new agreements with African and Brazilian
castor seed growers secure 900 tons of castor seeds, expected to
fulfill all standing orders by end of 2024.
- Biomica to present preliminary Phase 1 clinical
trial results for BMC128 at the 2024 ASCO conference on
June 3.
- Lavie Bio received
$2.5M, the second half of advanced
payment from Corteva; announced new collaboration with Syngenta for
bio insecticides; extended trials with Bayer for bio fungicides.
Marketing and sales for Yalos™ are expanding in the US and
Canada, with more crops
added.
- AgPlenus announced a new collaboration with Bayer,
including an upfront payment, research funding, milestone payments,
and future royalties; achieved a milestone with Corteva in an
existing collaboration agreement.
REHOVOT, Israel, May 23, 2024
/PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a
leading computational biology company aiming to revolutionize the
development of life-science-based products, today announced its
financial results for the first quarter period ended March 31, 2024.
Mr. Ofer Haviv, Evogene's
President and CEO, stated: "Evogene's mission is to direct and
accelerate the development of life-science based products. During
the past years we developed three innovative AI tech-engines
addressing the main development challenges of 3 life-science based
product categories:
- MicroBoost AI – for the development of microbe-based
products,
- ChemPass AI – for small-molecule-based products,
and
- GeneRator AI – for products based on genetic
elements.
Our AI tech-engines were structured to be compatible with the
tremendous potential of various market segments and not limited to
only one specific segment.
In order to capture the value of our AI tech-engines, our
business strategy is to establish diverse collaborative
partnerships through licensing or collaboration, with expert
partners in specific fields that complement our technology.
Together, we'll develop novel products, aiming for full or partial
ownership upon project completion.
This approach maximizes the potential of our AI tech-engines,
while reducing financial and development risks. We believe
this strategy holds the potential for groundbreaking innovations
and significant financial gains for Evogene.
Today, Evogene has 4 subsidiary companies, and diverse
engagements with leading companies in additional market segments,
not covered by our subsidiaries.
I am very pleased to share with you the main achievements made
by Evogene and its subsidiaries from the beginning of the
year."
Evogene Updates:
- Ceasing Canonic's operation - Evogene has decided to
cease its subsidiary Canonic, which specialized in customized
medical cannabis products, following challenging market conditions
in the medical cannabis sector. This decision results in annualized
savings of approximately $1.5
million. Resources will be reallocated to areas with greater
growth potential, such as funding Casterra's needs for on-going
capital.
- Establishment of Finally Foods - In March 2024, Evogene and The Kitchen FoodTech Hub
by Strauss Group, established Finally Foods Ltd., an AI-driven
company focused on sustainable protein production in plants, for
the food sector. Finally Foods will leverage Evogene's AI
technology to modify plants for efficient protein production. The
company has secured pre-seed funding from TKH and the Israeli
Innovation Authority. Evogene holds approximately 40% stake in the
company.
- Collaboration with Verb Biotics - In February 2024, Evogene and Verb Biotics entered
into a collaboration agreement to advance probiotic innovation by
developing new strains of probiotic bacteria that produce
sustainable quantities of microbial metabolites, which enhance
human health and vitality. The partnership will leverage Evogene's
MicroBoost AI tech-engine and Verb Biotics' expertise in
microbiome health.
Subsidiaries Updates:
Casterra Ag Ltd. – focuses on developing an integrated
solution to enable large-scale commercial cultivation of castor to
address the global demand for stable castor oil supply, mainly for
the biodiesel industry. Casterra is utilizing GeneRator
AI tech engine to direct and accelerate the development of its
unique elite castor seed varieties.
- Under the supervision of Casterra's new CEO, the company
has recently engaged with castor seed growers in Africa and Brazil. These engagements are expected to
yield approximately 900 tons of castor seeds in 2024, fulfilling
all existing purchase orders and providing additional inventory
later this year. The balance of the existing purchase orders is
anticipated to be delivered in the second half of 2024.
Biomica Ltd. - a clinical-stage biopharmaceutical company
developing innovative microbiome-based therapeutics, utilizing
Evogene's MicroBoost AI tech-engine.
- In January, 2024, Biomica reached a significant milestone
by completing Phase I trial enrollment for its microbiome-based
immuno-oncology drug BMC128 - a rationally designed consortia of 4
bacteria. Biomica recently announced that it will be presenting
preliminary Phase 1 study data of BMC128 in a poster presentation
at the 2024 ASCO Annual Conference, on June
3rd.
- Biomica is now preparing for advancing to Phase 2 of BMC128
clinical trial, and already conducted a pre-IND meeting with the
FDA, aiming to initiate Phase 2 in 2025.
- Results from Biomica's pre-clinical study in the IBS
program, conducted in collaboration with NYU's medical school, were presented at the
Digestive Disease Week 2024 Annual Conference in May 2024.
Lavie Bio Ltd. - a leading ag-biologicals company
that develops microbiome-based, computational-driven novel
bio-stimulant and bio-pesticide products, utilizing
Evogene's MicroBoost AI tech-engine.
- In February, 2024, Lavie Bio announced that it had met the
requirements of its licensing agreement for LAV311 & LAV312
with Corteva. This achievement enabled the successful receipt of
the second half of an advanced payment, amounting to $2.5 million, bringing the total to $5 million.
- In February, 2024, Lavie Bio signed an agreement with
Syngenta for the development of new biological insecticidal
solutions.
- Lavie Bio has extended its joint
validation trials with Bayer for its bio-fungicides, following
successful laboratory and greenhouse testing. This joint effort,
aimed at combating diseases affecting fruits and vegetables
globally, has moved to field experiments for further
validation.
- In March, 2024, Lavie Bio partnered with Ceres Global Ag
Corp. to integrate its bio-inoculant, Yalos™, into
regenerative agriculture programs across North America. This announcement and other
marketing and sales efforts support the penetration of
Yalos™ in US and Canada markets with additional crops being
added for treatment. Based on initial orders and sales projections,
2024 revenues are anticipated to increase compared to the previous
year.
AgPlenus Ltd. - a global leader in computational
design and development of novel sustainable crop protection
products, utilizing Evogene's ChemPass
AI tech-engine.
- In February, 2024, AgPlenus announced a licensing and
collaboration agreement with Bayer to develop a novel mode of
action broad-spectrum herbicide targeting the APTH1 protein. The
agreement entitles AgPlenus to an upfront payment, which was
received on March 2024, ongoing
research funding, milestone payments, and royalties based on future
product sales. Bayer will have the exclusive license for developing
and commercializing products resulting from this
collaboration.
- In March, 2024, AgPlenus announced achieving a milestone
under its existing collaboration with Corteva to develop new
herbicides through a novel mode of action, APCO12, discovered by
AgPlenus. The next phase of this collaboration will focus on
optimizing the herbicide candidates towards a commercial-level
product.
Financial Highlights:
Cash Position: As of March 31,
2024, Evogene held consolidated cash, cash equivalents, and
short-term bank deposits of approximately $26.6 million, compared to approximately
$31.1 million as of December 31, 2023. The consolidated cash usage
during the Q1 2024 was approximately $4.5
million. Excluding Lavie Bio
and Biomica, Evogene and its other subsidiaries used approximately
$3.4 million in cash. Projected cash
usage for 2024, excluding Lavie Bio
and Biomica, is expected to be around $8.0
million, marking a notable 36% decrease from approximately
$12.5 million in 2023.
Revenue: Revenues for the first quarter of 2024 were
approximately $4.2 million, a
significant increase from approximately $0.6
million in the same period the previous year. This growth
was primarily driven by revenues recognized from Lavie Bio's licensing agreement with Corteva and
AgPlenus's new collaboration with Bayer. Evogene anticipates
continued revenue growth in 2024 compared to the previous year,
mainly in the second half of 2024 based on Casterra's forecast for
seed-order supply.
R&D Expenses: Research and development expenses for
the first quarter of 2024 were stable at approximately $4.8 million, net of non-refundable grants,
consistent with the same period in the previous year.
Sales and Marketing Expenses: These expenses increased to
$992 thousand in the first quarter of
2024 compared to $800 thousand in the
same period of the previous year. The increase was driven by
heightened sales and marketing activities for Casterra's elite seed
varieties and Lavie Bio's first
commercial product, Yalos™.
General and Administrative Expenses: General and
administrative expenses rose to approximately $1.7 million in the first quarter of 2024,
compared to approximately $1.5
million in the same period of the previous year, mainly due
to non-cash compensation for subsidiary CEOs.
Other Expenses: The decision to cease Canonic's
operations resulted in recording other expenses of approximately
$0.5 million, mainly due to
impairment of fixed assets.
Operating Loss: The operating loss for the first quarter
of 2024 was approximately $4.1
million, a decrease from $6.8
million in the same period of the previous year, mainly due
to increased revenues.
Financing Income: Financing income net for the first
quarter of 2024 was $241 thousand,
compared to financing expenses net of $230
thousand in the same period of the previous year. This
improvement was primarily due to increased interest income and
revaluation of convertible SAFE.
Net Loss: The net loss for the first quarter of 2024 was
approximately $3.8 million, compared
to approximately $7.0 million in the
same period last year. The $3.2
million decrease in net loss was primarily due to increased
revenues and financial income, partially offset by the one-time
$519 thousand other expenses related
to ceasing Canonic's operations.
For the financial tables click here.
Conference Call & Webcast Details: Thursday, May 23, 2024. 9:00
AM EST 4:00 PM IDT
To join
the Zoom conference, please register in advance here
Or join via audio
Or, dial: US: +1 253 215 8782 or
+1 301 715 8592 or +1 305 224 1968 or +1 309 205 3325 or +1 312 626
6799 or +1 346 248 7799 or +1 360 209 5623 or +1 386 347 5053 or +1
507 473 4847 or +1 564 217 2000 or +1 646 558 8656 or +1 646 931
3860 or +1 669 444 9171 or +1 689 278 1000 or +1 719 359 4580 or +1
720 707 2699 or +1 253 205 0468
More International
numbers
Webinar ID: 871 1216 5951
Webcast & Presentation link available at:
https://evogene.com/investor-relations/
About Evogene Ltd.
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational
biology company leveraging big data and artificial intelligence,
aiming to revolutionize the development of life-science based
products by utilizing cutting-edge technologies to increase the
probability of success while reducing development time and
cost.
Evogene established three unique tech-engines – MicroBoost
AI, ChemPass AI and GeneRator AI. Each tech-engine is focused
on the discovery and development of products based on one of the
following core components: microbes (MicroBoost AI), small
molecules (ChemPass AI), and genetic elements (GeneRator
AI).
Evogene uses its tech-engines to develop products through
strategic partnerships and collaborations, and its
four subsidiaries including:
- Biomica Ltd. (www.biomicamed.com) – developing and
advancing novel microbiome-based therapeutics to treat human
disorders powered by MicroBoost AI;
- Lavie Bio (www.lavie-bio.com) –
developing and commercially advancing, microbiome based
ag-biologicals powered by MicroBoost AI;
- AgPlenus Ltd. (www.agplenus.com) – developing next
generation ag-chemicals for effective and sustainable crop
protection powered by ChemPass AI;
- Casterra Ag (www.casterra.co) – developing and marketing
superior castor seed varieties producing high yield and high-grade
oil content, on an industrial scale for the biofuel and other
industries powered by GeneRator AI.
For more information, please visit: www.evogene.com.
Forward-Looking Statements
This press release contains "forward-looking statements"
relating to future events. These statements may be identified by
words such as "may", "could", "expects", "hopes" "intends",
"anticipates", "plans", "believes", "scheduled", "estimates",
"demonstrates" or words of similar meaning. For example, Evogene
and its subsidiaries are using forward-looking statements in this
press release when they discuss Evogene's strategy, its
anticipated growth in 2024, projected 2024 cash usage, expected
annualized savings from ceasing Canonic's operations, Casterra's
ability to supply all existing purchase orders by the end of 2024
and providing additional inventory, the success of Biomica's
microbiome-based drugs in future trials, the results of the
validation trials of Lavie Bio with
Bayer, the anticipated revenues from sale of Yalos, Ag Plenus receipt of milestone and royalty
payments from Bayer and Ag Plenus
ability to reach commercial-level products in its project with
Corteva. Such statements are based on current expectations,
estimates, projections and assumptions, describe opinions about
future events, involve certain risks and uncertainties which are
difficult to predict and are not guarantees of future performance.
Therefore, actual future results, performance, or achievements of
Evogene and its subsidiaries may differ materially from what is
expressed or implied by such forward-looking statements due to a
variety of factors, many of which are beyond the control of Evogene
and its subsidiaries, including, without limitation, the current
war between Israel, Hamas and
Hezbollah and any worsening of the situation in Israel such as further mobilizations or
escalation in the northern border of Israel, and those risk factors contained in
Evogene's reports filed with the applicable securities authority.
In addition, Evogene and its subsidiaries rely, and expect to
continue to rely, on third parties to conduct certain activities,
such as their field trials and pre-clinical studies, and if these
third parties do not successfully carry out their contractual
duties, comply with regulatory requirements or meet expected
deadlines, Evogene and its subsidiaries may experience significant
delays in the conduct of their activities. Evogene and its
subsidiaries disclaim any obligation or commitment to update these
forward-looking statements to reflect future events or developments
or changes in expectations, estimates, projections and
assumptions.
CONSOLIDATED INTERIM
STATEMENTS OF FINANCIAL POSITION
|
U.S. dollars in
thousands
|
|
|
|
As of March 31,
|
|
As of December 31,
|
|
|
2024
|
|
2023
|
|
|
Unaudited
|
|
Audited
|
CURRENT ASSETS:
|
|
|
|
|
Cash and cash
equivalents
|
|
$11,915
|
|
$20,772
|
Short-term bank deposits
|
|
14,698
|
|
10,291
|
Trade
receivables
|
|
539
|
|
357
|
Other receivables and
prepaid expenses
|
|
3,154
|
|
2,973
|
Inventories
|
|
716
|
|
76
|
|
|
|
|
|
|
|
31,022
|
|
34,469
|
LONG-TERM ASSETS:
|
|
|
|
|
Long-term
deposits and other
receivables
|
|
26
|
|
28
|
Investment accounted
for using the equity method
|
|
133
|
|
-
|
Right-of-use-assets
|
|
879
|
|
980
|
Property, plant and
equipment, net
|
|
1,796
|
|
2,455
|
Intangible assets,
net
|
|
12,924
|
|
13,169
|
|
|
|
|
|
|
|
15,758
|
|
16,632
|
|
|
|
|
|
|
|
$
46,780
|
|
$
51,101
|
CURRENT LIABILITIES:
|
|
|
|
|
Trade
payables
|
|
$1,041
|
|
$
1,785
|
Employees and payroll
accruals
|
|
2,432
|
|
2,537
|
Lease
liability
|
|
715
|
|
853
|
Liabilities in
respect of government grants
|
|
561
|
|
388
|
Deferred revenues and
other advances
|
|
416
|
|
362
|
Other
payables
|
|
964
|
|
1,019
|
|
|
|
|
|
|
|
6,129
|
|
6,944
|
LONG-TERM LIABILITIES:
|
|
|
|
|
Lease
liability
|
|
286
|
|
285
|
Liabilities in
respect of government grants
|
|
4,237
|
|
4,426
|
Deferred revenues and
other advances
|
|
402
|
|
393
|
Convertible
SAFE
|
|
10,343
|
|
10,368
|
|
|
|
|
|
|
|
15,268
|
|
15,472
|
SHAREHOLDERS' EQUITY:
|
|
|
|
|
Ordinary shares of
NIS 0.02 par value:
Authorized −
150,000,000 ordinary shares; Issued and
outstanding – 50,623,278 shares as of March 31, 2024 and
50,584,888 shares as of December 31, 2023
|
|
286
|
|
286
|
Share premium and
other capital reserve
|
|
269,452
|
|
269,353
|
Accumulated
deficit
|
|
(261,449)
|
|
(257,586)
|
|
|
|
|
|
Equity attributable
to equity holders of the Company
|
|
8,289
|
|
12,053
|
|
|
|
|
|
Non-controlling
interests
|
|
17,094
|
|
16,632
|
|
|
|
|
|
Total
equity
|
|
25,383
|
|
28,685
|
|
|
|
|
|
|
|
$46,780
|
|
$
51,101
|
CONSOLIDATED INTERIM
STATEMENTS OF PROFIT OR LOSS
|
U.S. dollars in
thousands (except share and per share amounts)
|
|
|
|
Three months ended
March 31,
|
|
Year ended
December 31,
|
|
|
2024
|
|
2023
|
|
2023
|
|
|
Unaudited
|
|
Audited
|
|
|
|
|
|
|
|
Revenues
|
|
$
4,190
|
|
$
641
|
|
$
5,640
|
Cost of
revenues
|
|
310
|
|
322
|
|
1,692
|
|
|
|
|
|
|
|
Gross
profit
|
|
3,880
|
|
319
|
|
3,948
|
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development, net
|
|
4,801
|
|
4,800
|
|
20,777
|
Sales and
marketing
|
|
992
|
|
800
|
|
3,611
|
General and
administrative
|
|
1,654
|
|
1,515
|
|
6,068
|
Other expenses
|
|
519
|
|
-
|
|
-
|
|
|
|
|
|
|
|
Total operating
expenses, net
|
|
7,966
|
|
7,115
|
|
30,456
|
|
|
|
|
|
|
|
Operating
loss
|
|
(4,086)
|
|
(6,796)
|
|
(26,508)
|
|
|
|
|
|
|
|
Financing
income
|
|
407
|
|
308
|
|
1,486
|
Financing
expenses
|
|
(166)
|
|
(538)
|
|
(965)
|
|
|
|
|
|
|
|
Financing income
(expenses), net
|
|
241
|
|
(230)
|
|
521
|
|
|
|
|
|
|
|
Loss before taxes on
income
|
|
(3,845)
|
|
(7,026)
|
|
(25,987)
|
Tax
benefit
|
|
-
|
|
(45)
|
|
(33)
|
|
|
|
|
|
|
|
Loss
|
|
$ (3,845)
|
|
$ (6,981)
|
|
$
(25,954)
|
|
|
|
|
|
|
|
Attributable
to:
|
|
|
|
|
|
|
Equity holders of the
Company
|
|
(3,863)
|
|
(6,271)
|
|
(23,879)
|
Non-controlling
interests
|
|
18
|
|
(710)
|
|
(2,075)
|
|
|
|
|
|
|
|
|
|
$
(3,845)
|
|
$
(6,981)
|
|
$
(25,954)
|
|
|
|
|
|
|
|
Basic and diluted
loss per share, attributable to
equity holders of the Company
|
|
$ (0.08)
|
|
$ (0.15)
|
|
$
(0.52)
|
|
|
|
|
|
|
|
Weighted average
number of shares used in
computing basic and diluted loss per share
|
|
50,622,922
|
|
41,489,001
|
|
45,685,619
|
CONSOLIDATED INTERIM
STATEMENTS OF CASH FLOWS
|
|
U.S. dollars in
thousands
|
|
|
|
|
|
Three months ended
March 31,
|
|
Year ended
December 31,
|
|
|
|
2024
|
|
2023
|
|
2023
|
|
|
|
Unaudited
|
|
Audited
|
|
|
|
|
|
|
|
|
|
Cash flows from operating
activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss
|
|
$ (3,845)
|
|
$ (6,981)
|
|
$ (25,954)
|
|
|
|
|
|
|
|
Adjustments to
reconcile loss to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustments to the
profit or loss items:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation
|
|
426
|
|
401
|
|
1,641
|
Amortization of
intangible assets
|
|
245
|
|
240
|
|
971
|
Share-based
compensation
|
|
539
|
|
418
|
|
1,877
|
Revaluation of
convertible SAFE
|
|
(25)
|
|
194
|
|
254
|
Net financing
income
|
|
(194)
|
|
(54)
|
|
(666)
|
Loss (gain) from sale
and impairment of property, plant
|
|
|
|
|
|
|
and
equipment
|
|
519
|
|
(26)
|
|
(26)
|
Tax
benefit
|
|
-
|
|
(45)
|
|
(33)
|
|
|
|
|
|
|
|
|
|
1,510
|
|
1,128
|
|
4,018
|
Changes in asset and
liability items:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Decrease (increase)
in trade receivables
|
|
(182)
|
|
98
|
|
(9)
|
Increase in other
receivables
|
|
(179)
|
|
(291)
|
|
(1,445)
|
Decrease (increase)
in inventories
|
|
(640)
|
|
(25)
|
|
490
|
Decrease in deferred
taxes
|
|
-
|
|
94
|
|
94
|
Increase (decrease)
in trade payables
|
|
(685)
|
|
121
|
|
742
|
Increase (decrease)
in employees and payroll accruals
|
|
(105)
|
|
55
|
|
550
|
Decrease in other
payables
|
|
(61)
|
|
(553)
|
|
(534)
|
Increase (decrease)
in deferred revenues and other advances
|
|
(71)
|
|
8
|
|
(288)
|
|
|
|
|
|
|
|
|
|
(1,923)
|
|
(493)
|
|
(400)
|
|
|
|
|
|
|
|
Cash received (paid)
during the year for:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
received
|
|
171
|
|
138
|
|
905
|
Interest
paid
|
|
(23)
|
|
(36)
|
|
(115)
|
Taxes paid
|
|
-
|
|
-
|
|
(31)
|
|
|
|
|
|
|
|
Net cash used in
operating activities
|
|
$
(4,110)
|
|
$
(6,244)
|
|
$ (21,577)
|
CONSOLIDATED INTERIM
STATEMENTS OF CASH FLOWS
|
U.S. dollars in
thousands
|
|
|
|
|
|
|
|
|
|
|
|
Three months
ended
|
|
|
Year
ended
|
March
31,
|
|
December
31,
|
|
|
2024
|
|
2023
|
|
|
2023
|
|
|
Unaudited
|
|
|
Audited
|
|
|
|
|
|
|
|
|
Cash flows from investing
activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of property,
plant and equipment
|
|
$
(141)
|
|
$
(359)
|
|
$ (785)
|
Proceeds from sale of
marketable securities
|
|
-
|
|
637
|
|
6,924
|
Purchase of marketable
securities
|
|
-
|
|
-
|
|
(503)
|
Proceeds from sale of
property, plant and equipment
|
|
10
|
|
26
|
|
26
|
Investment in bank
deposits, net
|
|
(4,231)
|
|
-
|
|
(10,200)
|
|
|
|
|
|
|
|
Net cash provided by
(used in) investing activities
|
|
(4,362)
|
|
304
|
|
(4,538)
|
|
|
|
|
|
|
|
Cash flows from financing
activities:
|
|
|
|
|
|
|
|
Issuance of a
subsidiary preferred shares to non-controlling interests
|
|
-
|
|
-
|
|
9,523
|
Proceeds from issuance
of ordinary shares, net of issuance expenses
|
|
3
|
|
268
|
|
8,449
|
Repayment of lease
liability
|
|
(231)
|
|
(206)
|
|
(836)
|
Proceeds from
government grants
|
|
-
|
|
26
|
|
1,089
|
Repayment of government
grants
|
|
(139)
|
|
(35)
|
|
(73)
|
|
|
|
|
|
|
|
Net cash provided
by (used in) financing activities
|
|
(367)
|
|
53
|
|
18,152
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exchange rate
differences - cash and cash equivalent balances
|
|
|
(18)
|
|
(93)
|
|
|
(245)
|
|
|
|
|
|
|
|
|
|
Decrease in cash and
cash equivalents
|
|
|
(8,857)
|
|
(5,980)
|
|
|
(8,208)
|
|
|
|
|
|
|
|
|
|
Cash and cash
equivalents at the beginning of the period
|
|
|
20,772
|
|
28,980
|
|
|
28,980
|
|
|
|
|
|
|
|
|
|
Cash and cash
equivalents at the end of the period
|
|
|
$
11,915
|
|
$
23,000
|
|
|
$ 20,772
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Significant non-cash activities
|
|
|
|
|
|
|
|
|
Acquisition of
property, plant and equipment
|
|
|
$
22
|
|
$
69
|
|
|
$
81
|
|
|
|
|
|
|
|
|
|
Investment in
equity-accounted investee with corresponding
deferred revenues
|
|
|
133
|
|
-
|
|
|
-
|
|
|
|
|
|
|
|
|
|
Increase of
right-of-use asset recognized with corresponding
lease liability
|
|
|
$
130
|
|
$
71
|
|
|
$
194
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Evogene Investors Relations
Contact:
Rachel Pomerantz
Gerber, Head of Investor Relations at Evogene
Email: rachel.pomerantz@evogene.com
Tel: +972-8-9311901
Logo -
https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/evogene-reports-first-quarter-2024-financial-results-302154117.html
SOURCE Evogene